ViewRay Incorporated Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
Published: May 31, 2012
"FDA clearance of our integrated system is a major milestone in the development of our technology," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "It has already been an exciting year for ViewRay, with an additional round of funding and the installation of our first research systems at major U.S. medical centers. Early clinical imaging studies have verified the quality of the system's MR images, and now we're looking forward to clinical applications." The ViewRay system provides continuous soft-tissue imaging during treatment so that clinicians can see and record precisely where radiation therapy is being delivered, as it's being delivered.
ViewRay's patented cancer treatment technology was invented by company founder James F. Dempsey, PhD, while he was a member of the radiation oncology faculty at the University of Florida. "ViewRay began with the idea that we need to see what exactly we're doing when we treat cancer patients with radiation therapy," said Dempsey, now ViewRay's chief scientific officer. "Thanks to our clear vision, an outstanding engineering team, and dedicated leadership, we're now able to bring that idea into the clinic, where it can help cancer patients."
ViewRay recently closed the final tranche of a $45 million round of Series C venture capital financing intended to advance the ViewRay system toward commercialization. The first ViewRay system is installed at the Siteman Cancer Center at BarnesJewish Hospital and Washington University School of Medicine, where early imaging studies have taken place. Additional ViewRay partners include the UCLA Jonsson Comprehensive Cancer Center and the University of Wisconsin Carbone Cancer Center, where a ViewRay system is currently being installed.
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.
ViewRay is a trademark of ViewRay Incorporated.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.
SOURCE ViewRay Incorporated